summari ew report underli revenu
underli beat consensu
estim adj ep also top
consensu estim ew underli
global thv transcathet heart valv sale
underli fell shi consensu
modestli expect thv growth
reflect mid-teen growth us market growth
europewher ew saw addit share loss primarili result
aggress competitor price pipelin front
major develop neg surpris importantli ew still
expect launch sapien ultra europ
centera commerci implant expect resum
europ late term outlook ew re-affirmed
underli sale growth guidanc expect
report sale higher-end guidanc rang
wed note underli sale growth guidanc impli
acceler growth midpoint
bottom line ew increas adj ep guidanc
midpoint report due
perform lower project tax rate ew guid
total sale report adj ep
report
bigger pictur thought ew head next quarter
remain somewhat cautiou given lack obviou catalyst
soft european tavr busi howev expect
thing get better ew behind eu
launch sapien ultra centera expect resum
european commerci implant late clinic revenu
associ cap continu access protocol
tmtt transcathet mitral
transcathet tricuspid aid lessen cardioband suppli
constraint would expect underli growth rel
similar model underli growth acceler
current model could prove
conserv look ahead believ ew well-
posit acceler top-lin growth driven low-risk
centera ultra mitral cardioband pascal current
model ew growth report acceler vs
underli growth remain bullish ew share
given outlook next month would
recommend investor buy weak els equal
continu next page
compani data secur llc estim reuter
note share trade hour trade
compani prioriti stock list
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
estim chang lower sale estim underli
due fx rais adj ep estim report maintain
sale estim report adj ep estim report
rais price target assum adj ep estim
tavr miss street expect underli ww thv sale came
street expect discuss compani recent investor dayew
longer provid break-out us ou thv sale ew estim ww procedur grew mid-
teen compani growth lower due ou dynam regard us market
manag said procedur growth roughli in-lin ew growth mid-teen ou outsid
us ew said tavr sale grew around ex-fx europ specif ew note procedur
growth broader market double-digit due share loss primarili relat aggress
competitor price addit ew call signific declin ta transap
procedur surpris also result share loss base compani
commentari estim ew us tavr sale ou sale
underli estim ew tavr sale europ low-single-digit growth
japan tavr sale get insight ou market dynam report
earn august ew re-affirmed full-year thv guidanc higher-end
dollar rang higher-end underli growth guidanc impli
step-up vs growth
chang centera ultra timelin ew said chang timelin next-gen
ultra self-expand centera tavr valv regard ultra manag note continu
enrol patient small clinic studi supplement european regulatori submiss compani
still expect ce mark fda approv later year separ manag said complet
minor modif centera deliveri system ew said track resum commerci implant
initi pivot trial latter part
transcathet mitral tricuspid expect regard commerci activ ew
record cardioband mr sale in-lin due continu suppli constraint
despit slow start commerci ew still expect tmtt product contribut sale
ramp throughout year regard pascal clasp ce mark trial expect complet
put launch time track us ef earli feasibl studi remain on-going
ew note pleas progress tmvr transcathet mitral valv replac devic
cardiaq sapien formal updat given lastli harpoon implant remain paus
ew continu examin complic aros hand patient earli clinic
studi ew expect materi impact shv sale manag remain optimist
long-term prospect devic
shv growth driven inspiri intuiti elit ew report shv surgic heart valv sale
underli beat consensu estim result
benefit ew premium surgic valv product inspiri intuiti elit drove sale
growth faster procedur volum growth manag note acceler physician adopt
inspiri includ strong traction younger patient ou manag still expect launch
inspiri japan later year provid reimburs place ew re-affirmed
underli growth expect shv busi continu expect shv sale
come toward higher-end rang
critic growth acceler ew report critic cc sale
underli beat consensu estim respect result
driven compani hemospher advanc monitor platform aid new gpo group
purchas organ contract us ew continu expect critic care underli growth
come higher end rang post full-year cc sale higher-end
top-lin outlook re-affirmed adj ep rais call ew re-affirmed
underli sale growth outlook addit manag continu expect total
sale come toward higher-end guidanc rang report basi thv
ew expect sale higher-end rang higher-end underli
growth guidanc ew expect shv sale higher-end rang underli
cc come higher-end rang higher-end underli
guidanc regard currenc impact sale fx expect tailwind
vs previous move ew reiter guidanc item
gross margin sg dilut share count notabl ew
tax rate lower end previou guidanc bottom line ew
increas adj ep guidanc midpoint report due
perform lower project tax rate ew guid total sale
report adj ep report
metricswfconsensusrevenu us aortic heart mitral heart heart valv growthtot oper factset revenu margin compani report secur llc estim factset visibl alpha explicitli state consensu visibl alpha may vari base broker contribut medic technolog
price target
price target assum ep estim risk includ greater
share loss model delay mitral program neg clinic data
believ upcom data pipelin product help ew address new competit
transcathet mitral valv opportun signific catalyst
irvin california -base edward lifesci ew develop manufactur market product
design heart valv diseas cardiac surgeri critic care edward revenu reach
billion come transcathet heart valv therapi thv busi ew
player transcathet heart valv therapi market
edward lifesci incom statementin million except per share good sold excl gross oper oper expens expens incom pre-tax debt net adj dilut analysi gross bp bp bp oper bp growthnet incom dilut oper share qtr/qtr except dilut compani report secur llc estim edward lifesci corpor
